Latest Period
Q4 2025
Security Snapshot
ARS Pharmaceuticals, Inc. - Common Stock (SPRY) Institutional Ownership
CUSIP: 82835W108
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
188
Shares (Excl. Options)
88,986,225
Price
$11.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- SPRY on Nasdaq
- Shares outstanding
- 99,325,542
- Price per share
- $8.05
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 88,986,225
- Total reported value
- $1,036,491,602
- % of total 13F portfolios
- 0%
- Share change
- +5,012,619
- Value change
- +$65,098,638
- Number of holders
- 188
- Price from insider filings
- $8.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SPRY - ARS Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 82835W108.
- 188 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 188 to 124 between Q4 2025 and Q1 2026.
- Reported value moved from $1,036,491,602 to $287,457,319.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 188 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 82835W108?
CUSIP 82835W108 identifies SPRY - ARS Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 82835W108:
Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | $111,050,917 | 10,940,977 | RA Capital Management, L.P. | 29 Sep 2025 | |||
| Flynn James E | 7.8% | -12% | $134,624,739 | -$18,102,531 | 7,610,217 | -12% | Deerfield Management Company, L.P. | 30 Jul 2025 |
| Rubric Capital Management LP | 6.3% | $70,556,000 | 6,200,000 | Rubric Capital Management LP | 31 Dec 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 6% | +12% | $48,748,087 | +$4,322,622 | 5,916,030 | +9.7% | Millennium Management LLC | 27 Mar 2026 |
| BlackRock, Inc. | 5% | -2.4% | $39,719,688 | -$534,702 | 4,946,412 | -1.3% | BlackRock, Inc. | 31 Mar 2026 |
As of 31 Dec 2025, 188 institutional investors reported holding 88,986,225 shares of ARS Pharmaceuticals, Inc. - Common Stock (SPRY). This represents 90% of the company’s total 99,325,542 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) together control 76% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 10,860,977 | 0% | 1.3% | $126,530,382 |
| ORBIMED ADVISORS LLC | 8.3% | 8,288,510 | 0% | 2.1% | $96,561,142 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 7.6% | 7,503,812 | 0% | 1.1% | $87,419,410 |
| Rubric Capital Management LP | 6.2% | 6,200,000 | +38% | 0.86% | $72,230,000 |
| BlackRock, Inc. | 5.1% | 5,085,317 | +5.3% | 0% | $59,243,944 |
| SR One Capital Management, LP | 4% | 4,012,903 | 0% | 6.6% | $46,750,320 |
| Aberdeen Group plc | 3.6% | 3,556,049 | +15% | 0.06% | $41,427,971 |
| VANGUARD GROUP INC | 3.5% | 3,509,174 | +0.25% | 0% | $40,881,877 |
| STATE STREET CORP | 3.2% | 3,223,581 | +11% | 0% | $37,554,719 |
| MILLENNIUM MANAGEMENT LLC | 3.2% | 3,168,406 | 0.03% | $36,911,930 | |
| FRANKLIN RESOURCES INC | 2.6% | 2,543,097 | +6.1% | 0.01% | $29,627,082 |
| UBS Group AG | 2.2% | 2,210,866 | +235% | 0.01% | $25,756,589 |
| Tyro Capital Management LLC | 2% | 1,994,852 | 7.2% | $23,240,025 | |
| CITADEL ADVISORS LLC | 2% | 1,954,472 | +23% | 0.02% | $22,769,599 |
| Casdin Capital, LLC | 1.6% | 1,600,000 | 0% | 1.2% | $18,640,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,552,870 | +3.1% | 0% | $18,093,898 |
| Southpoint Capital Advisors LP | 1.5% | 1,500,000 | 0% | 0.41% | $17,475,000 |
| Janney Montgomery Scott LLC | 1.3% | 1,287,832 | +6.2% | 0.03% | $15,003,000 |
| BAMCO INC /NY/ | 1.3% | 1,268,532 | 0% | 0.04% | $14,778,398 |
| GOLDMAN SACHS GROUP INC | 0.82% | 812,036 | -39% | 0% | $9,460,219 |
| FIL Ltd | 0.82% | 810,073 | 0.01% | $9,437,350 | |
| LEVIN CAPITAL STRATEGIES, L.P. | 0.75% | 747,506 | -2.2% | 0.76% | $8,708,445 |
| Nextech Invest, Ltd. | 0.67% | 660,703 | 0% | 0.74% | $7,697,190 |
| BANK OF MONTREAL /CAN/ | 0.65% | 643,407 | 0% | $7,495,692 | |
| CenterBook Partners LP | 0.57% | 568,361 | +11% | 0.32% | $6,621,406 |
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock (SPRY) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 35,798,773 | $287,457,319 | +$16,829,674 | $8.03 | 124 |
| 2025 Q4 | 88,986,225 | $1,036,491,602 | +$65,098,638 | $11.65 | 188 |
| 2025 Q3 | 83,632,743 | $840,434,931 | -$93,311,095 | $10.05 | 187 |
| 2025 Q2 | 84,521,210 | $1,475,027,148 | +$149,943,852 | $17.45 | 185 |
| 2025 Q1 | 76,226,291 | $958,937,759 | +$63,838,841 | $12.58 | 182 |
| 2024 Q4 | 71,304,827 | $752,320,202 | +$68,074,351 | $10.55 | 163 |
| 2024 Q3 | 63,765,651 | $925,913,322 | +$31,092,478 | $14.50 | 148 |
| 2024 Q2 | 62,590,275 | $533,041,807 | +$21,909,612 | $8.51 | 112 |
| 2024 Q1 | 59,892,345 | $612,088,771 | -$16,199,586 | $10.22 | 113 |
| 2023 Q4 | 65,423,068 | $358,517,051 | -$2,784,476 | $5.48 | 99 |
| 2023 Q3 | 66,524,840 | $251,464,826 | +$38,754,815 | $3.78 | 94 |
| 2023 Q2 | 55,071,412 | $368,976,724 | +$11,246,123 | $6.70 | 92 |
| 2023 Q1 | 53,405,274 | $347,669,060 | +$19,586,591 | $6.51 | 88 |
| 2022 Q4 | 50,164,476 | $427,856,540 | +$173,112,031 | $8.53 | 72 |
| 2022 Q3 | 30,422,972 | $160,377,408 | +$24,492,078 | $5.28 | 58 |
| 2022 Q2 | 26,061,019 | $110,514,000 | -$387,734 | $4.24 | 60 |
| 2022 Q1 | 26,983,988 | $94,707,000 | -$19,556,342 | $3.51 | 66 |
| 2021 Q4 | 30,103,833 | $200,460,000 | -$13,223,479 | $6.66 | 71 |
| 2021 Q3 | 28,894,700 | $288,363,500 | -$42,490,899 | $9.98 | 73 |
| 2021 Q2 | 27,989,545 | $864,603,729 | +$5,243,899 | $30.89 | 74 |
| 2021 Q1 | 27,691,694 | $1,205,836,321 | +$139,058,596 | $43.63 | 67 |
| 2020 Q4 | 24,444,347 | $1,127,544,026 | +$1,117,084,030 | $46.34 | 61 |